Document |
Document Title |
WO/2023/087632A1 |
The present invention belongs to the field of medicinal chemistry, and specifically disclosed are an anti-inflammatory analgesic compound and the use thereof. The compound of the present invention is a compound having a structure shown i...
|
WO/2023/090974A1 |
The present invention provides a method for preparing a high-purity arylethene compound through a simple process with a high yield.
|
WO/2023/091490A1 |
Novel ionizable lipids and lipid nanoparticles that can be used in the delivery of therapeutic cargos are disclosed.
|
WO/2023/085256A1 |
The present invention provides a fluorine-containing ether compound which is represented by the following formula. R1-O-R2-CH2-R3-CH2-R4-CH2-R5-CH2-R6-CH2 -R7-CH2-R8-O-R9 (In the formula, R3, R5 and R7 represent same perfluoropolyether c...
|
WO/2023/085271A1 |
The present invention provides a fluorine-containing ether compound which is represented by the following formula. R1-O-R2-CH2-R3-CH2-OCH2CH(OH)CH2O-CH2-R4-CH2-R5-O-R6 (In the formula, R3 and R4 represent same or different perfluoropolye...
|
WO/2023/085894A1 |
The present invention relates to a novel thiourea derivative as an activator of RORα and a pharmaceutical composition comprising same. A compound according to the present invention is expected to be effective in the treatment and preven...
|
WO/2023/078950A1 |
The current invention relates to ionizable lipid-like compound according to Formula (I) or pharmaceutically acceptable salt, tautomer, or stereoisomer thereof. The present invention also provides a lipid nanoparticle comprising an ioniza...
|
WO/2023/078946A1 |
The current invention relates to ionizable lipid-like compound according to Formula (I) or pharmaceutically acceptable salt, tautomer, or stereoisomer thereof. The present invention also provides a lipid nanoparticle comprising an ioniza...
|
WO/2023/077235A1 |
The present invention discloses novel pentamidine analogues such as pentamidine analogs having the general formula: (1a) wherein: X is C, N, or –CH-CH-, Y is Y1 when X is N, and Y is Y1 and Y2 when X is C, or –CH-CH-, Y1, or Y1 and Y...
|
WO/2023/076302A1 |
A process for preparation of benzoate salt of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-h
ydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile,
designated herein as Compound (A), and methods of using Compound (A)...
|
WO/2023/077094A1 |
The present disclosure provides methods for the treatment of major depressive disorder (MDD) by administering cariprazine or a pharmaceutically acceptable salt thereof, as an adjunct to antidepressant therapy in the treatment of subjects...
|
WO/2023/074936A1 |
The present disclosure relates to a bifunctional compound using a UBR box domain-binding ligand. The UBR box domain is a domain commonly present in the UBR (Ubiquitin protein ligase E3 component n-recognin) protein of the N-end rule path...
|
WO/2023/066190A1 |
The disclosure relates to the compounds as GPR183 inhibitors, the methods for preparing these compounds, and the compositions and their uses as treatment or prevention of cancers, autoimmune diseases, pain, and osteoporosis using GPR183 ...
|
WO/2023/066971A1 |
The present invention relates to novel trimetazidine salts, leading to a reduced formation of trimetazidine nitrosamine in presence of nitrites.
|
WO/2022/115971A9 |
Disclosed are methods for separating, recovering, and purifying CBGA, CBDVA, THCVA, CBCVA, and CBCA from dewatered and desolventized crude complex extracts or mixtures of metabolites, cannabinoids, and cannabis phytochemicals. The method...
|
WO/2023/057097A1 |
The present invention is comprised in the field of medicinal chemistry, and it is related to substituted vinyl piperazine-piperidine urea compound which are well effective as antitumoral agents. In particular, they are suitable in method...
|
WO/2023/057358A1 |
A process for the production of bis(pyrrolidino)butane (BPB), the process comprising the reaction of pyrrolidine (PYR) in the presence of hydrogen, a heterogeneous catalyst (catalyst) and optionally 1,4-butanediole (BDO) in the liquid ph...
|
WO/2023/056365A2 |
The present application is directed to inhibitors of iRhom2/ADAM17 activity that are useful in the treatment of various diseases.
|
WO/2023/053008A1 |
The present invention relates to oximes, their synthesis, and their use for increasing GBA activity and/or levels as well as treatment of GBA-related diseases, such as Parkinson's disease.
|
WO/2023/046768A1 |
The invention relates a method for producing amine N-oxide compounds of the formula (I) or (II), in which the R1 are selected from hydrocarbon groups with 4 to 26 C atoms and optionally at least one O or S atom; R2, R3, and R5 are select...
|
WO/2023/046330A1 |
A continuous process for the separation of a mixture comprising pyrrolidine, bis(pyrrolidino)butane and water, the process comprising the following steps: A) separating a mixture stream (1) by distillation into a low-boiler stream (2) co...
|
WO/2023/049808A2 |
The present disclosure relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, compositions comprising same, and methods of using the compounds and compositions to treat various cancers.
|
WO/2023/044574A1 |
Disclosed are novel phosphorylated and sulfonated mescaline derivative compounds and pharmaceutical and recreational drug formulations containing the same. The compounds may be produced by reacting a precursor mescaline derivative with a...
|
WO/2023/043040A1 |
The present invention provides a novel compound for a light-emitting device, and an organic light-emitting device comprising same.
|
WO/2023/040106A1 |
Disclosed in the present invention is a preparation method for an acetamide compound by means of green visible-light catalysis. In the method, LED lamps are used as light sources to provide energy, and economically available aromatic ami...
|
WO/2023/036148A1 |
Provided in the present invention are a cationic lipid compound and the use thereof, which relate to the field of biomedicines. A lipid nanoparticle prepared from the cationic lipid compound as represented by formula I in the present inv...
|
WO/2023/036945A1 |
The invention relates to a compound of formula (I) wherein A is NH or CH2; G1 is a linear or a cyclic alkyl; Y1 is CH or N; Y2 is O, N or CH, W is O, N or CH; Z is NH or O; X1 and X2 and R, and R1 to R8 are functional groups.
|
WO/2023/038456A1 |
The present invention relates to a novel compound, and a use thereof for treating emotional behavioral disorders. A pharmaceutical composition containing the novel compound according to the present invention for preventing or treating em...
|
WO/2023/030667A1 |
A process for the preparation of a compound of formula (II) where Et = ethyl; Bn = benzyl and Ph = phenyl; comprises the step of reacting a cyclic amine with an alkylating agent to form a compound of formula II, wherein the process is so...
|
WO/2023/029928A1 |
An amino lipid and an application thereof: using ethenesulfonyl fluoride (ESF), a dual-function electrophile, to build an amine head group and a hydrophobic chain into an amino lipid, fully utilizing the click chemical reaction propertie...
|
WO/2023/033044A1 |
Provided is a fluorine-containing ether compound represented by the following formula. R1-[B]-[A]-O-CH2-R2-CH2-O-[C]-[D]-R3 (wherein, R1 denotes a C7-18 organic group including a group in which an aromatic hydrocarbon and a nitrogen atom...
|
WO/2023/035005A2 |
The present invention provides a dual inhibitor that inhibits histone deacetylase 6 (HDAC6) and heat shock protein 90 (HSP90) for amelioration and/or treatment of tumors through removal of immune suppression from tumor microenvironments ...
|
WO/2023/026884A1 |
To provide a curable composition that generates little outgas from an obtained cured product. The curable composition includes a radical polymerization initiator represented by formula 1 and a radical polymerizable compound. In formula 1...
|
WO/2023/025854A1 |
The present invention relates to malonamide compounds of the formula (I) where the variables are as defined in the claims and the description, and to compositions comprising these compounds. The invention also relates to the use of said ...
|
WO/2023/024515A1 |
The present invention provides a lipid compound which can be used alone or in combination with other lipid components such as neutral lipids, charged lipids, steroids and/or analogs thereof, and/or polymer-conjugated lipids to form lipid...
|
WO/2023/025915A1 |
The present invention is based on the finding that the compounds disclosed herein bind to, preferably harmful, protein-oligomers and thereby induce a conformational change of the latter. This conformational change enhances the recognitio...
|
WO/2023/023316A1 |
Disclosed are compositions and methods for the preservation, storage, and transport of living biological tissues, organs, and populations of isolated cells. In particular, the compositions and methods permit mammalian cells, tissues, and...
|
WO/2023/017752A1 |
The present invention addresses the problem of providing a resin composition and an adhesive that are highly curable and have a high photocuring adhesive strength with UV light having a longer wavelength (for example, 405 nm) and that ar...
|
WO/2023/017269A1 |
The invention relates to compounds of formula (I) and to their use in treating or preventing an inflammatory disease or a disease associated with an undesirable immune response: (I) wherein RA and RB are as defined herein.
|
WO/2023/008127A1 |
An actinic ray-sensitive or radiation-sensitive resin composition is provided which has excellent storage stability and which enables excellent pattern shapes to be obtained when forming fine patterns (specifically, with a line width or ...
|
WO/2023/007147A1 |
This invention relates to therapeutic 6-substituted naphthalene-1,3- disulfonic acid derivatives of formula (I) (Formula (I)). More specifically, the invention relates to compounds of formula (I) useful as modulators of extracellular nic...
|
WO/2023/008345A1 |
The present invention provides: an active light sensitive or radiation sensitive resin composition which contains a compound (I) that produces an acid when irradiated with active light or radiation, while having an ionic structure and a ...
|
WO/2023/009521A1 |
This disclosure pertains to the preparation of bifunctional compounds (e.g., Compound 1), intermediates in the preparation of such compounds, and preparation of such intermediates. Compound 1
|
WO/2023/001323A1 |
The present invention relates to a lipidoid of general formula I, wherein X is selected from -C(=O)NH-, -C(=O)O-, -C(=S)O-, -C(=O)S-, -C(=S)S-, -C(=O)NHNH-, -CH2-, -O-, -OC(=O)-, -S-, -SC(=O)-, -NH-, -NHNH-, -NHC(=O)-, -NHNHC(=O)-, -C≡...
|
WO/2023/002011A1 |
The present invention concerns novel Gram-negative bacteria efflux pump inhibitors. It further relates to the use of Gram-negative bacteria efflux pump inhibitors to prevent and/or treat antibiotic resistance by potentiating the activity...
|
WO/2023/284420A1 |
The present invention provides a polycyclic aryl compound S1 for preparing a drug for antifungal infection. The structural formula of the polycyclic compound is S1. The polycyclic aryl compound having the shell-core structure and represe...
|
WO/2021/048809A9 |
The present invention relates to novel heterocyclic compounds of general formula (I) their tautomers, stereoisomers, enantiomers, pharmaceutically acceptable salts and pharmaceutical composition. The compounds of general formula (I) belo...
|
WO/2023/285787A1 |
A process for preparing a compound of formula I, or a salt thereof, as defined herein. Also, compounds of formula I and intermediate compounds useful in the preparation of a compound of formula I.
|
WO/2023/285072A1 |
The present invention relates to compound of formula (I), a diastereomer, enantiomer, crystal or co-crystal thereof, or a pharmaceutically acceptable salt, or mixture thereof. The present invention also relates to pharmaceutical composit...
|
WO/2023/285788A1 |
A process for preparing a compound of formula (I), or a salt thereof, as defined herein. Also, compounds of formula I and intermediate compounds useful in the preparation of a compound of formula (I).
|